Comparative Pharmacology
Head-to-head clinical analysis: TOBRADEX versus TOBRASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOBRADEX versus TOBRASONE.
TOBRADEX vs TOBRASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobradex is a combination of tobramycin (an aminoglycoside antibiotic) and dexamethasone (a corticosteroid). Tobramycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Tobrasone is a combination of tobramycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and dexamethasone (a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis).
1-2 drops into the affected eye(s) every 4-6 hours; in severe disease, every 1-2 hours initially, then taper. Ointment: apply a 1/2-inch ribbon into the conjunctival sac 3-4 times daily.
2 mg (as 0.2% topical solution) applied to the affected area twice daily. Not for ophthalmic use.
None Documented
None Documented
Tobramycin: 2-3 hours in adults with normal renal function; prolonged to 24-60 hours in anuria. Dexamethasone: 36-54 hours.
Terminal elimination half-life is 2.5-3.5 hours in adults, supporting twice-daily dosing for maintenance therapy.
Tobramycin: ~90% renal (glomerular filtration), <1% biliary. Dexamethasone: hepatic metabolism, metabolites renally excreted.
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of the dose, with biliary/fecal excretion contributing 20-30%.
Category C
Category C
Ophthalmic antibiotic/steroid combination
Ophthalmic antibiotic/steroid combination